Newland Pharmaceutical Co., Ltd. (SHE:301277)
China flag China · Delayed Price · Currency is CNY
9.80
+0.03 (0.31%)
Jul 29, 2026, 4:00 PM EDT

Newland Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
100.78121.25173.63158.98132.3114.98
Depreciation & Amortization
55.0755.0737.8431.0824.2420.86
Other Amortization
2.472.472.231.540.16-
Loss (Gain) From Sale of Assets
----0.070.440.21
Asset Writedown & Restructuring Costs
1.491.492.621.460.320.11
Loss (Gain) From Sale of Investments
-10.44-10.44-13.95-17.6-1.52-0.17
Provision & Write-off of Bad Debts
-0.87-0.872.27-3.62.2311.14
Other Operating Activities
-26.928.635.05-0.656.296.54
Change in Accounts Receivable
66.0366.03-82.3117.51-146.8-99.16
Change in Inventory
-32.92-32.92-18.2521.625.05-29.15
Change in Accounts Payable
-93.4-93.417.32-54.728.4520
Change in Other Net Operating Assets
-1.6-1.60.3-0.485.283.9
Operating Cash Flow
60.92116.94126.76259.4682.8549.08
Operating Cash Flow Growth
-54.57%-7.75%-51.14%213.19%68.80%2.55%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-63.77-101.38-110.79-96.51-74.34-25.4
Sale of Property, Plant & Equipment
0.040.060.140.540.040.06
Investment in Securities
-92.55-13.9578.28129.46-691.5-8.5
Other Investing Activities
-1.72---0.330
Investing Cash Flow
-158-115.28-32.3633.48-765.47-33.83

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
----89.09118.46
Total Debt Issued
----89.09118.46
Long-Term Debt Repaid
--1.8-3.25-2.75-203.05-100
Total Debt Repaid
-1.8-1.8-3.25-2.75-203.05-100
Net Debt Issued (Repaid)
-1.8-1.8-3.25-2.75-113.9618.46
Issuance of Common Stock
----838.574
Common Dividends Paid
-112.02-112.02-80.02-66.68-6.77-36.7
Other Financing Activities
0.81----19.09-6.94
Financing Cash Flow
-113.01-113.82-83.26-69.43698.74-21.19

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Cash Flow
-210.09-112.1611.14223.5116.12-5.94

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-2.8515.5515.97162.948.523.68
Free Cash Flow Growth
--2.63%-90.20%1816.39%-64.10%-23.36%
Free Cash Flow Margin
-0.43%2.31%2.20%25.01%1.35%4.61%
Free Cash Flow Per Share
-0.010.040.040.420.030.08
Levered Free Cash Flow
-33.9422.3329.72158.98-11.33-12.63
Unlevered Free Cash Flow
-33.8722.4629.78159.06-7.03-8.43

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
39.1238.5853.7243.5966.6843.77
Change in Working Capital
-60.64-60.64-82.9388.32-81.62-104.59